Alphamab Oncology (HK:9966)
:9966
Top Page
Alphamab Oncology
(9966)
Select Model
Select Model
Rating:53Neutral
Price Target:
HK$9.00
▼(-0.44% Downside)
Action:ReiteratedDate:11/28/25
Alphamab Oncology's overall stock score is primarily influenced by strong revenue growth and improved profitability, offset by significant concerns in cash flow generation and a high P/E ratio indicating potential overvaluation. Technical analysis provides mixed signals, with bearish momentum and potential overbought conditions.
Positive Factors
Revenue Growth
A >200% revenue jump and a move from HK$218.8M to HK$640.1M indicate strong product uptake or successful commercialization. Sustained top-line expansion strengthens R&D reinvestment capacity, supports scaling costs, and improves the odds of durable cash generation if conversion to operating cash follows.
Negative Factors
Weak Cash Generation
Zero operating and free cash flow despite reported profit signals fragile cash conversion from sales. Over months this forces reliance on financing, partnerships, or milestone receipts to fund R&D and commercialization, raising execution and liquidity risk during scale-up.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
A >200% revenue jump and a move from HK$218.8M to HK$640.1M indicate strong product uptake or successful commercialization. Sustained top-line expansion strengthens R&D reinvestment capacity, supports scaling costs, and improves the odds of durable cash generation if conversion to operating cash follows.
Read all positive factors
Alphamab Oncology (9966) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$8.81B
Dividend YieldN/A
Average Volume (3M)3.94M
Price to Earnings (P/E)―
Beta (1Y)1.64
Revenue Growth206.58%
EPS GrowthN/A
CountryHK
Employees420
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.15
Shares Outstanding974,293,700
10 Day Avg. Volume3,868,184
30 Day Avg. Volume3,937,702
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)1.76
Price to Sales (P/S)5.03
P/FCF Ratio16.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$9.60Price Target Upside6.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.15
Revenue Forecast (FY)HK$422.97M
Alphamab Oncology Business Overview & Revenue Model
Company Description
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune che...
How the Company Makes Money
Alphamab Oncology generates revenue primarily through the development and sale of its therapeutic products. The company’s revenue model includes direct sales of its approved therapies to hospitals and clinics, as well as licensing agreements with ...
Alphamab Oncology Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
60
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 785.96M | 640.08M | 218.77M | 166.84M | 146.02M | 0.00 |
| Gross Profit | 725.19M | 579.77M | 163.54M | 122.64M | 142.99M | 0.00 |
| EBITDA | 243.26M | 156.79M | -129.30M | -391.83M | -358.13M | -390.47M |
| Net Income | 232.81M | 166.34M | -210.59M | -325.72M | -412.42M | -427.77M |
Balance Sheet | ||||||
| Total Assets | 2.36B | 2.24B | 2.14B | 2.12B | 2.71B | 2.64B |
| Cash, Cash Equivalents and Short-Term Investments | 1.64B | 1.57B | 1.41B | 1.35B | 1.99B | 2.06B |
| Total Debt | 273.48M | 185.96M | 257.08M | 345.39M | 637.27M | 222.81M |
| Total Liabilities | 503.95M | 409.87M | 465.00M | 559.86M | 834.80M | 366.44M |
| Stockholders Equity | 1.85B | 1.83B | 1.67B | 1.56B | 1.87B | 2.27B |
Cash Flow | ||||||
| Free Cash Flow | 217.62M | 190.56M | -239.02M | -429.96M | -478.72M | -438.00M |
| Operating Cash Flow | 256.48M | 212.34M | -202.84M | -300.31M | -320.60M | -347.18M |
| Investing Cash Flow | -496.65M | -92.93M | -18.11M | 850.76M | 574.26M | -1.52B |
| Financing Cash Flow | -75.05M | -98.96M | 218.07M | -310.90M | 363.90M | 186.58M |
Alphamab Oncology Technical Analysis
Positive
9.04
Price Trends
8.69
Positive
9.49
Negative
9.79
Negative
Market Momentum
-0.09
Negative
57.92
Neutral
65.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9966, the sentiment is Positive. The current price of 9.04 is above the 20-day moving average (MA) of 8.39, above the 50-day MA of 8.69, and below the 200-day MA of 9.79, indicating a neutral trend. The MACD of -0.09 indicates Negative momentum. The RSI at 57.92 is Neutral, neither overbought nor oversold. The STOCH value of 65.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:9966.
Alphamab Oncology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | HK$9.02B | 135.64 | 7.17% | ― | 23.37% | ― | |
54 Neutral | HK$18.02B | -22.61 | -12.74% | ― | -76.58% | -4.90% | |
53 Neutral | HK$8.81B | -76.25 | -6.26% | ― | 206.58% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$12.80B | 5.89 | 18.28% | ― | 59.70% | 239.97% | |
45 Neutral | HK$2.42B | -14.44 | -27.70% | ― | -100.00% | 30.68% | |
40 Underperform | HK$11.43B | 30.77 | 24.17% | ― | 240.05% | -140.09% |
* Healthcare Sector Average
HK:9966
Alphamab Oncology
9.04
3.11
52.45%
HK:1672
Ascletis Pharma, Inc.
16.98
12.03
243.03%
HK:2142
HBM Holdings Ltd.
14.47
9.04
166.48%
HK:2157
Lepu Biopharma Co. Ltd. Class H
6.15
2.89
88.65%
HK:2256
Abbisko Cayman Limited
13.26
7.07
114.22%
HK:3681
SinoMab Bioscience Ltd.
1.76
0.59
50.43%
Alphamab Oncology Corporate Events
Alphamab Oncology’s KN035 NDA for First-Line Biliary Tract Cancer Accepted by China’s NMPA
Jan 9, 2026
Alphamab Oncology announced that China’s National Medical Products Administration has accepted its new drug application for KN035 (Envafolimab, ENWEIDA) in combination with GEMOX chemotherapy as a first-line treatment for unresectable or met...
Alphamab Wins CDE Acceptance for Phase II Trial of Novel Cervical Cancer Therapy JSKN033
Dec 29, 2025
Alphamab Oncology announced that China’s Center for Drug Evaluation has officially accepted its Investigational New Drug application for a phase II clinical trial of JSKN033, a high-concentration subcutaneous co-formulation of a HER2 bispeci...
Alphamab Oncology’s JSKN003 Receives FDA Breakthrough Therapy Designation
Dec 18, 2025
Alphamab Oncology announced that its breakthrough HER2-targeting ADC, JSKN003, has been granted Breakthrough Therapy Designation (BTD) by the FDA for advanced platinum-resistant ovarian and related cancers, signaling the therapy’s clinical p...
Alphamab Oncology Advances Revolutionary JSKN027 ADC to Clinical Stage
Dec 17, 2025
Alphamab Oncology announced that its Investigational New Drug (IND) application for JSKN027, a first-in-class PD-L1/VEGFR2 bispecific antibody-drug conjugate (ADC), has been officially accepted by China’s Center for Drug Evaluation (CDE). Th...
Alphamab Oncology Initiates HK$30 Million Share Repurchase Plan
Nov 7, 2025
Alphamab Oncology announced a decision to repurchase up to HK$30 million worth of its own shares from the open market, as authorized by a mandate approved at their annual general meeting. This move is intended to reflect the company’s confid...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.